NKP-1339

Item number	Size	Delivery time	Price
TGM-TQ0016-2mg	2 mg	7 - 10 business days*	198.00€
TGM-TQ0016-5mg	5 mg	7 - 10 business days*	345.00€
TGM-TQ0016-1mL	1 ml	7 - 10 business days*	381.00€
TGM-TQ0016-25mg	25 mg	7 - 10 business days*	1,140.00€
TGM-TQ0016-50mg	50 mg	7 - 10 business days*	1,490.00€
TGM-TQ0016-100mg	100 mg	7 - 10 business days*	1,991.00€

If you have any questions, please use our Contact Form.
You can also order by e-mail: info@biomol.com
Larger quantity required? Request bulk

Description: NKP-1339 (IT-139) induces G2/M cell cycle arrest, blockage of DNA synthesis, and... more

Close menu

Product information "NKP-1339"

Description: NKP-1339 (IT-139) induces G2/M cell cycle arrest, blockage of DNA synthesis, and induction of apoptosis via the mitochondrial pathway. Target: DNA/RNA Synthesis. Smiles: [Na+].[Cl-][Ru+3]([Cl-])([Cl-])([Cl-])([N]1=CC=2C=CC=CC2N1)[N]3=CC=4C=CC=CC4N3. References: Robert Trondl, et al. NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application. Chemical Science. Chemical Science

Keywords:	KP-1339, IT-139
Supplier:	TargetMol
Supplier-Nr:	TQ0016

Properties

MW:	502.14 D
Formula:	C14H12Cl4N4NaRu

Database Information

CAS :

197723-00-5| Matching products

Handling & Safety

Storage:	-20°C
Shipping:	+4°C (International: +4°C)

Caution
Our products are for laboratory research use only: Not for administration to humans!

Information about the product reference will follow. more

Close menu

You will get a certificate here

Go back

Read, write and discuss reviews... more

Close menu

Customer review for "NKP-1339"

Write a review